[
  {
    "ts": null,
    "headline": "Analysis: Innovent's weight-loss drug highlights China challenge for Novo, Lilly",
    "summary": "SHANGHAI (Reuters) -Innovent Biologics' newly launched weight-loss drug is making inroads in its home market of China, ramping up competition with its Western rivals as it pursues a marketing strategy that is gaining traction.  Xinermei, launched in July, is the third once-weekly injectable GLP-1 weight management therapy available in China after Novo Nordisk's Wegovy and Eli Lilly's Mounjaro.  Those were introduced in late 2024 and January 2025 respectively, several months after their own approvals, into a Chinese weight-loss drug market that is expected by analysts to be worth billions in the coming years.",
    "url": "https://finnhub.io/api/news?id=360aea5887bf62337dddef0d530308f973e0d52e1900159d14cf71458cc98a9d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758582195,
      "headline": "Analysis: Innovent's weight-loss drug highlights China challenge for Novo, Lilly",
      "id": 136850304,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "SHANGHAI (Reuters) -Innovent Biologics' newly launched weight-loss drug is making inroads in its home market of China, ramping up competition with its Western rivals as it pursues a marketing strategy that is gaining traction.  Xinermei, launched in July, is the third once-weekly injectable GLP-1 weight management therapy available in China after Novo Nordisk's Wegovy and Eli Lilly's Mounjaro.  Those were introduced in late 2024 and January 2025 respectively, several months after their own approvals, into a Chinese weight-loss drug market that is expected by analysts to be worth billions in the coming years.",
      "url": "https://finnhub.io/api/news?id=360aea5887bf62337dddef0d530308f973e0d52e1900159d14cf71458cc98a9d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer joining GLP-1 race: How Novo & Eli Lilly compare",
    "summary": "Pfizer (PFE) is entering the weight-loss drug race with its acquisition of Metsera. BMO Capital Markets managing director of biopharma equity research Evan Seigerman Yahoo Finance Head of News Myles Udland on Market Domination to discuss how investors can play the GLP-1 trade in the pharmaceutical sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=2a97c38ed56329e72c1038cab397f0480622db64fd59451ea74acc8fdd3bed0d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758574800,
      "headline": "Pfizer joining GLP-1 race: How Novo & Eli Lilly compare",
      "id": 136850305,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) is entering the weight-loss drug race with its acquisition of Metsera. BMO Capital Markets managing director of biopharma equity research Evan Seigerman Yahoo Finance Head of News Myles Udland on Market Domination to discuss how investors can play the GLP-1 trade in the pharmaceutical sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=2a97c38ed56329e72c1038cab397f0480622db64fd59451ea74acc8fdd3bed0d"
    }
  },
  {
    "ts": null,
    "headline": "Metsera: Long-Acting MET-097i And Product Differentiation Nets Pfizer Acquisition",
    "summary": "Metsera, Inc. is being acquired by Pfizer Inc. for up to $7.3 billion, driven by its innovative obesity drug pipeline. Click to read why MTSR is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=672546e5b973028908d86da56bd98a1fa63364fadd28e94952e97f8445426233",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758556556,
      "headline": "Metsera: Long-Acting MET-097i And Product Differentiation Nets Pfizer Acquisition",
      "id": 136844155,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2223801264/image_2223801264.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Metsera, Inc. is being acquired by Pfizer Inc. for up to $7.3 billion, driven by its innovative obesity drug pipeline. Click to read why MTSR is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=672546e5b973028908d86da56bd98a1fa63364fadd28e94952e97f8445426233"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Jumps Back into the Weight-Loss Race With $4.9B Acquisition",
    "summary": "Pfizer said it would buy a clinical stage biopharma company for up to $7 billion, as it eyes the lucrative weight-loss drug market currently dominated by Eli Lilly and Novo Nordisk.",
    "url": "https://finnhub.io/api/news?id=9b8c8de28a969383d59e5af39e03e393f1cff5e9dbef571b046ed9e90d96a1d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758554220,
      "headline": "Pfizer Jumps Back into the Weight-Loss Race With $4.9B Acquisition",
      "id": 136850306,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer said it would buy a clinical stage biopharma company for up to $7 billion, as it eyes the lucrative weight-loss drug market currently dominated by Eli Lilly and Novo Nordisk.",
      "url": "https://finnhub.io/api/news?id=9b8c8de28a969383d59e5af39e03e393f1cff5e9dbef571b046ed9e90d96a1d0"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion",
    "summary": "The deal returns the drug-maker to the growing market for obesity drugs after scrapping an experimental weight-loss pill.",
    "url": "https://finnhub.io/api/news?id=541cc41b589b3df8b4e2e82bbbf7d27b4f89c3a32b0b9c084930f3a935f31e7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758552840,
      "headline": "Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion",
      "id": 136850307,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The deal returns the drug-maker to the growing market for obesity drugs after scrapping an experimental weight-loss pill.",
      "url": "https://finnhub.io/api/news?id=541cc41b589b3df8b4e2e82bbbf7d27b4f89c3a32b0b9c084930f3a935f31e7a"
    }
  },
  {
    "ts": null,
    "headline": "Alzheimer’s Drug Franchise Decides Eli Lilly And Co.’s (LLY) Performance",
    "summary": "Macquarie Asset Management, an investment management company, released its “Macquarie Large Cap Growth Fund” investor letter for the second quarter of 2025. A copy of the letter can be downloaded here. The second quarter of 2025 endured significant government policy changes and geopolitical events, which resulted in volatility yet ended with robust performance for equity […]",
    "url": "https://finnhub.io/api/news?id=d263e1c38a25537f3df42c3ee64578b4569ed77fb34b6200a0a6565450945bc4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758544704,
      "headline": "Alzheimer’s Drug Franchise Decides Eli Lilly And Co.’s (LLY) Performance",
      "id": 136850308,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Macquarie Asset Management, an investment management company, released its “Macquarie Large Cap Growth Fund” investor letter for the second quarter of 2025. A copy of the letter can be downloaded here. The second quarter of 2025 endured significant government policy changes and geopolitical events, which resulted in volatility yet ended with robust performance for equity […]",
      "url": "https://finnhub.io/api/news?id=d263e1c38a25537f3df42c3ee64578b4569ed77fb34b6200a0a6565450945bc4"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer ramps up obesity treatments push with 4.9 billion dollar deal for Metsera",
    "summary": "Demand for obesity treatments has soared in recent years.",
    "url": "https://finnhub.io/api/news?id=748d52633e4b2b1da19f7b797a126b90ea4edfad1b910d067a540332171e8c4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758544035,
      "headline": "Pfizer ramps up obesity treatments push with 4.9 billion dollar deal for Metsera",
      "id": 136850309,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Demand for obesity treatments has soared in recent years.",
      "url": "https://finnhub.io/api/news?id=748d52633e4b2b1da19f7b797a126b90ea4edfad1b910d067a540332171e8c4e"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly Stock a Buy After Gaining 10% in 1 Month?",
    "summary": "The drugmaker continues to lead the increasingly competitive market for weight management drugs.",
    "url": "https://finnhub.io/api/news?id=ccb505da79a436e983da59c67305c5ed0b8aaae7bf2eb72dc8f8ecd7057f2996",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758543900,
      "headline": "Is Eli Lilly Stock a Buy After Gaining 10% in 1 Month?",
      "id": 136850310,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drugmaker continues to lead the increasingly competitive market for weight management drugs.",
      "url": "https://finnhub.io/api/news?id=ccb505da79a436e983da59c67305c5ed0b8aaae7bf2eb72dc8f8ecd7057f2996"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer seals up to $7.3bn takeover of weight loss drugmaker Metsera",
    "summary": "Pfizer has sealed an up to $7.3bn takeover of weight-loss drug developer Metsera in the biggest deal yet by a large pharmaceutical group trying...",
    "url": "https://finnhub.io/api/news?id=692f664f7c449a67518e4fc24fe417ab39deabe03b7ebf75afb719e0b388474f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758540746,
      "headline": "Pfizer seals up to $7.3bn takeover of weight loss drugmaker Metsera",
      "id": 136850311,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer has sealed an up to $7.3bn takeover of weight-loss drug developer Metsera in the biggest deal yet by a large pharmaceutical group trying...",
      "url": "https://finnhub.io/api/news?id=692f664f7c449a67518e4fc24fe417ab39deabe03b7ebf75afb719e0b388474f"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Metsera Acquisition Is The Missing Piece Of The Obesity Puzzle",
    "summary": "Pfizer Inc. acquires Metsera, Inc. for up to $7.5B, boosting its obesity pipeline with new therapies. Click for potential FDA action and the impact on PFE and MTSR.",
    "url": "https://finnhub.io/api/news?id=19babe5762d139880f0fd0145590c8b38d0f9dfcad1c250d24d334e5d7fb97ea",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758540434,
      "headline": "Pfizer: Metsera Acquisition Is The Missing Piece Of The Obesity Puzzle",
      "id": 136842761,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2222078293/image_2222078293.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. acquires Metsera, Inc. for up to $7.5B, boosting its obesity pipeline with new therapies. Click for potential FDA action and the impact on PFE and MTSR.",
      "url": "https://finnhub.io/api/news?id=19babe5762d139880f0fd0145590c8b38d0f9dfcad1c250d24d334e5d7fb97ea"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Buys Obesity Drug Developer Metsera: Buy Today And Benefit From CVRs",
    "summary": "Pfizer Inc. acquires Metsera, Inc. to re-enter the obesity drug market. Click for my look at PFZ and MTSR stock and where I see value in the weight loss sector.",
    "url": "https://finnhub.io/api/news?id=5bfff513063fe49ab6c7824a71faf28231baceff3d5fefb0fa928a0b51860a29",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758536408,
      "headline": "Pfizer Buys Obesity Drug Developer Metsera: Buy Today And Benefit From CVRs",
      "id": 136842565,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1299632091/image_1299632091.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. acquires Metsera, Inc. to re-enter the obesity drug market. Click for my look at PFZ and MTSR stock and where I see value in the weight loss sector.",
      "url": "https://finnhub.io/api/news?id=5bfff513063fe49ab6c7824a71faf28231baceff3d5fefb0fa928a0b51860a29"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer doubles down on weight-loss treatments with up to $7.3 billion Metsera buyout",
    "summary": "(Reuters) -Pfizer said on Monday it would acquire drug developer Metsera in a deal valued at up to $7.3 billion, including future payments, as it seeks to gain a foothold in the fast-growing obesity treatment market.  The global obesity drug market, projected to reach $150 billion by early 2030s, is fueled by the rapid adoption of GLP-1 therapies from companies such as Novo Nordisk and Eli Lilly.  Metsera brings its portfolio of experimental obesity drugs, with MET-097i, a GLP-1 injectable, and MET-233i, which mimics the pancreatic hormone amylin, being the key among them.",
    "url": "https://finnhub.io/api/news?id=1e8ce91ef8cdfc09b120d5c789fa5e2e631201927611c215faa214dc67002aa4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758513857,
      "headline": "Pfizer doubles down on weight-loss treatments with up to $7.3 billion Metsera buyout",
      "id": 136850312,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Reuters) -Pfizer said on Monday it would acquire drug developer Metsera in a deal valued at up to $7.3 billion, including future payments, as it seeks to gain a foothold in the fast-growing obesity treatment market.  The global obesity drug market, projected to reach $150 billion by early 2030s, is fueled by the rapid adoption of GLP-1 therapies from companies such as Novo Nordisk and Eli Lilly.  Metsera brings its portfolio of experimental obesity drugs, with MET-097i, a GLP-1 injectable, and MET-233i, which mimics the pancreatic hormone amylin, being the key among them.",
      "url": "https://finnhub.io/api/news?id=1e8ce91ef8cdfc09b120d5c789fa5e2e631201927611c215faa214dc67002aa4"
    }
  }
]